title: [The effect of substituting latanoprost 0.005% for unoprostone 0.12%].
abstract: OBJECTIVE
  To evaluate the effect of substituting latanoprost(LAT) 0.005% for unoprostone(UNO) 0.12% after a trial of unilateral treatment.
  
  
  METHODS
  We treated 30 patients with primary open-angle glaucoma(n = 8), ocular hypertension (n = 1), or normal-tension glaucoma(n = 21) with UNO for 4 weeks in one eye and then substituted LAT for UNO. Four weeks later we measured the intraocular pressure(IOP) in the ipsilateral eye.
  
  
  RESULTS
  The mean baseline IOP level was 18.6 +/- 3.8(mean +/- standard deviation) mmHg. The mean IOP levels(reduction rates) after UNO and LAT therapy were 16.7 +/- 3.1 mmHg (16.6%) and 14.1 +/- 3.2 mmHg (28.9%), respectively(p < 0.001). All patients who responded to UNO also responded to LAT; however, 55% of those who did not respond to UNO responded to LAT.
  
  
  CONCLUSIONS
  If LAT is substituted for UNO, it can be predicted that 63.3% of the patients will respond.
authors.affiliation: Department of Ophthalmology and Visual Science, Osaka University Medical School, 2-2 Yamadaoka, Suita 565-0871, Japan.
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Otori
authors.forename: Hideki
authors.initials: H
authors.lastname: Tokugawa
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Morimura
authors.forename: Masaki
authors.initials: M
authors.lastname: Okada
authors.forename: Hiroya
authors.initials: H
authors.lastname: Goto
authors.forename: Atsuya
authors.initials: A
authors.lastname: Miki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Tano
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015237:Dinoprost / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D005260:Female; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; C072630:isopropyl unoprostone; D000077338:Latanoprost; D015237:Dinoprost